Moving Toward a More Sustainable Future With pMDIs

Pressurized metered dose inhalers (pMDIs) are relied on by patients across the globe for the convenient, effective relief and sustained management of conditions such as asthma and Chronic Obstructive Pulmonary Disease (COPD). However, their environmental impact is a growing concern; developing more sustainable pMDIs is a pressing goal. This article outlines Aptar Pharma’s ability to support metered dose inhaler developers and manufacturers with this transition. HFC 152a and HFO1234ze are the leading replacement propellant candidates, with both offering much lower Global Warming Potential that the fluorocarbons currently used. Aptar Pharma is investing in R&D to explore the use of these propellants with existing metering valves, working with multiple model formulation and valve configurations to support the transition to low carbon inhalers.